LBI-1123

THERAPEUTIC AREA

BRAIN CANCER

LBI-1123

Indications:
Glioblastoma & Metastatic
REGULATORY PATHWAY

New NDA

TARGET INDICATION

First-in-class 3rd generation taxane that crosses the blood brain barrier (BBB) to treat Brain Cancer

CURRENT DEVELOPMENT STATUS

API synthesis in process, expect first availability in May 2019. Anticipate using Lumnus nano platform to create multiple analogues and rational drug combinations. Development will pause after formulation is complete and until funding and staff resources are secured

NEXT DEVELOPMENT PHASE

Screen multiple candidates, by performing safety & efficacy testing in animals

TIME TO HUMAN BENEFIT

Human trials to begin as soon as 1.5 years from funding & staffing

IMMEDIATE FUNDING REQUIREMENT

Yes, please inquire